NCT06029270 2026-04-13
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT06295159 2026-04-01
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03521830 2026-03-20
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03026140 2026-03-05
NICHE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT06999980 2026-02-19
Neo IRENIE
Melanoma Institute Australia
Phase 2 Recruiting
NCT06151236 2026-02-17
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Melanoma Institute Australia
Phase 2 Recruiting
NCT04080804 2026-02-09
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT06624475 2026-02-05
NEON
University of California, San Diego
Phase 2 Recruiting
NCT05704647 2026-01-14
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05428007 2026-01-05
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Recruiting
NCT06237920 2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04205552 2024-05-09
NEOpredict
University Hospital, Essen
Phase 2 Recruiting